Clinical Trial Update: Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

An extension study evaluating the safety and efficacy of Atiprimod for neuroendocrine carcinoma has completed its Phase 2 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• Atiprimod

Snippet

Sponsor: Callisto Pharmaceuticals | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED